Classifications: blood formers, coagulators, and anticoagulants; low molecular weight heparin
Pregnancy Category: B
30 mg/0.3 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL injection
Low molecular weight heparin with antithrombotic properties. Does not affect PT. Does affect thrombin time (TT) and activated thromboplastin time (aPTT) up to 1.8 times the control value.
Antithrombotic properties are due to its antifactor Xa and antithrombin (antifactor IIa) in the coagulation activities. An effective anticoagulation agent; used for prophylactic treatment as an antithrombotic agent following certain types of surgery.
Prevention of deep vein thrombosis (DVT) after hip, knee, or abdominal surgery, treatment of DVT and pulmonary embolism, management of acute coronary syndrome.
Patients with active major bleeding, GI bleeding, hemophilia, heparin hypersensitivity, heparin-induced thrombocytopenia (HIT), thrombocytopenia associated with an antiplatelet antibody in the presence of enoxaparin, bleeding disorders, idiopathic thrombocytopenia purpura (ITP), hypersensitivity to enoxaparin; porcine protein hypersensitivity, neonates.
Uncontrolled arterial hypertension, recent history of GI disease, benzyl alcohol hypersensitivity, conditions or surgery with increased risk of bleeding, hepatic disease, hypertension, coagulopathy, thrombolytic therapy, thrombocytopenia, dental disease, dental work, diabetic retinopathy, dialysis, diverticulitis, inflammatory bowel disease, intramuscular injections, lumbar puncture, menstruation, obesity, peptic ulcer disease, older adults, endocarditis, renal disease, renal impairment, spinal anesthesia, stroke, surgery, pregnancy (category B), lactation. Safety and effectiveness in children are not established.
|Prevention of DVT after Hip or Knee Surgery
Adult: SC 30 mg b.i.d. for 1014 d starting 1224 h post-surgery
Prevention of DVT after Abdominal Surgery
Adult: SC 40 mg q.d. starting 2 h before surgery and continuing for 710 d (max: 12 d)
Treatment of DVT and Pulmonary Embolus
Adult: SC 1 mg/kg q12h or 1.5 mg/kg/d; monitor anti-Xa activity to determine appropriate dose
Acute Coronary Syndrome
Adult: SC 1 mg/kg q12h for 28 d, give concurrently with aspirin 100325 mg/d
Adjustment for Renal Impairment
Clcr <30 mL/min: 30 mg or 1 mg/kg q24h
Assessment & Drug Effects
Patient & Family Education